^
    Back
    Association details:
    Biomarker:NRAS expression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma

    Published date:
    12/07/2020
    Excerpt:
    ...lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in advanced HCC patients...sorafenib eliminated MET- and NRAS-expressing tumors.
    DOI:
    10.1158/1078-0432.CCR-20-3382